Zacks: Analysts Anticipate IDEXX Laboratories, Inc. (NASDAQ:IDXX) to Announce $1.13 EPS
Wall Street brokerages forecast that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will report earnings of $1.13 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for IDEXX Laboratories’ earnings, with the lowest EPS estimate coming in at $1.12 and the highest estimate coming in at $1.14. IDEXX Laboratories reported earnings per share of $1.05 during the same quarter last year, which would suggest a positive year-over-year growth rate of 7.6%. The company is expected to issue its next quarterly earnings report on Thursday, November 7th.
On average, analysts expect that IDEXX Laboratories will report full-year earnings of $4.86 per share for the current fiscal year, with EPS estimates ranging from $4.84 to $4.88. For the next year, analysts anticipate that the firm will report earnings of $5.57 per share, with EPS estimates ranging from $5.44 to $5.65. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. The business had revenue of $620.10 million for the quarter, compared to analyst estimates of $627.10 million. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The company’s revenue was up 6.8% on a year-over-year basis.
In related news, Chairman Jonathan W. Ayers sold 10,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $272.75, for a total transaction of $2,727,500.00. Following the completion of the sale, the chairman now owns 1,035,942 shares of the company’s stock, valued at $282,553,180.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rebecca M. Henderson sold 4,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $271.17, for a total value of $1,084,680.00. Following the sale, the director now directly owns 14,696 shares of the company’s stock, valued at approximately $3,985,114.32. The disclosure for this sale can be found here. Insiders have sold 73,305 shares of company stock valued at $19,402,442 in the last ninety days. Corporate insiders own 2.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in IDXX. Bigelow Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 2.8% in the second quarter. Bigelow Investment Advisors LLC now owns 1,363 shares of the company’s stock valued at $375,000 after acquiring an additional 37 shares during the period. Captrust Financial Advisors lifted its holdings in IDEXX Laboratories by 32.5% in the second quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock valued at $42,000 after acquiring an additional 37 shares during the period. Ropes Wealth Advisors LLC lifted its holdings in IDEXX Laboratories by 0.5% in the second quarter. Ropes Wealth Advisors LLC now owns 7,293 shares of the company’s stock valued at $2,008,000 after acquiring an additional 38 shares during the period. Nordea Investment Management AB lifted its holdings in IDEXX Laboratories by 0.9% in the first quarter. Nordea Investment Management AB now owns 4,485 shares of the company’s stock valued at $1,003,000 after acquiring an additional 40 shares during the period. Finally, Western Wealth Management LLC lifted its holdings in IDEXX Laboratories by 0.7% in the second quarter. Western Wealth Management LLC now owns 5,669 shares of the company’s stock valued at $1,562,000 after acquiring an additional 40 shares during the period. 87.04% of the stock is owned by hedge funds and other institutional investors.
Shares of IDXX stock traded down $5.58 during trading hours on Friday, reaching $265.47. 343,980 shares of the company’s stock were exchanged, compared to its average volume of 369,301. IDEXX Laboratories has a 1 year low of $176.11 and a 1 year high of $292.17. The stock has a market cap of $23.33 billion, a PE ratio of 62.32 and a beta of 0.85. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 4.49. The stock’s fifty day moving average price is $278.73 and its two-hundred day moving average price is $253.27.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.